肿瘤药学2024，Vol.14Issue(4)：503-507,5.DOI:10.3969/j.issn.2095-1264.2024.04.18
1例卵巢癌患者使用贝伐珠单抗联合TC化疗方案致血小板减少症的药学监护
Pharmacological care for an ovarian cancer patient with thrombocytopenia caused by bevacizumab combined with TC chemotherapy
摘要
Abstract
Objective To observe the clinical characteristics of a case of ovarian cancer patient with thrombocytopenia caused by bevacizumab combined with TC chemotherapy regimen,and to explore the therapeutic regimen and pharmacological supervision.Methods Clinical pharmacists analyzed the clinical data of the ovarian cancer patient who experienced throm-bocytopenia after receiving bevacizumab in combination with TC chemotherapy,and reviewed the literature to optimize the treatment plan,and assisted the doctors to jointly provide pharmacological supervision for the patient.Results With super-vision of clinical pharmacists,the patient was improved after receiving platelet elevating therapy,and the platelet count rose to the normal level.Conclusion Clinical pharmacists provide pharmacological monitoring for patients during their treatment from a professional perspective,and assist clinicians in formulating individualized treatment plans,which helps to ensure the safety of patients' medication and promote the rational use of medication.关键词
卵巢癌/贝伐珠单抗/化疗/血小板减少症/药学监护Key words
Ovarian cancer/Bevacizumab/Chemotherapy/Thrombocytopenia/Pharmacological monitoring分类
医药卫生引用本文复制引用
林素芬,梁丽仪,曾卫强,厉婷,徐道华,常宁..1例卵巢癌患者使用贝伐珠单抗联合TC化疗方案致血小板减少症的药学监护[J].肿瘤药学,2024,14(4):503-507,5.基金项目
佛山市卫生健康局医学科研课题(20240720A010411). （20240720A010411）
